Trials / Completed
CompletedNCT02127476
A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's Disease (AD) or Mild to Moderate AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK6640 | Single ascending dose and multiple ascending doses administration |
| DRUG | Matching Placebo | Single ascending dose and multiple ascending doses administration |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
- First posted
- 2014-04-30
- Last updated
- 2024-06-17
Locations
9 sites across 5 countries: Belgium, Finland, Netherlands, Serbia, Sweden
Source: ClinicalTrials.gov record NCT02127476. Inclusion in this directory is not an endorsement.